en POLSKI
eISSN: 2083-8441
ISSN: 2081-237X
Pediatric Endocrinology Diabetes and Metabolism
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

without publication fees

Journal integrated with

integrated with publons
1/2024
vol. 30
 
Share:
Send email
Share:
abstract:
Review paper

Precocious puberty and other endocrine disorders during mitotane treatment for paediatric adrenocortical carcinoma – case series and literature review

Elżbieta Moszczyńska
1
,
Marta Baszyńska-Wilk
1
,
Aleksandra Tutka
1
,
Agnieszka Bogusz-Wójcik
1
,
Patrycja Dasiewicz
1
,
Olga Gryniewicz-Kwiatkowska
2
,
Małgorzata Walewska-Wolf
3
,
Maria Stepaniuk
4
,
Dorota Majak
4
,
Wiesława Grajkowska
4

  1. Department of Endocrinology and Diabetology, The Children’s Memorial Health Institute, Warsaw, Poland
  2. Department of Oncology, The Children’s Memorial Health Institute, Warsaw, Poland
  3. Gynaecological Outpatient Clinic, The Children’s Memorial Health Institute, Warsaw, Poland
  4. Department of Pathology, The Children’s Memorial Health Institute, Warsaw, Poland
Pediatr Endocrinol Diabetes Metab 2024; 30 (1): 14-28
DOI: https://doi.org/10.5114/pedm.2023.133315
Online publish date: 2024/02/29
View full text Get citation
 
PlumX metrics:
Introduction
Adrenocortical carcinoma (ACC) is rare and an aggressive tumour. Mitotane is the mainstay adjuvant drug in treating ACC. The study aimed to describe patients diagnosed with precocious puberty (PP) and other endocrinological complications during mitotane therapy.

Material and methods
This retrospective study enrolled 4 patients with ACC treated with mitotane therapy complicated by PP. We analysed clinical manifestations, radiological, histopathological findings, and hormonal results.

Results
The median age at the diagnosis of ACC was 1.5 years. All patients were treated with surgery and mitotane, accompanied by chemotherapy regimens in 2 cases. The median time from surgery to the initiation of mitotane therapy was 26 days. During mitotane treatment, PP was confirmed based on symptoms, and hormonal and imaging tests. In one patient, incomplete peripheral PP was followed by central PP. The median time from the therapy initiation to the first manifestations of PP was 4 months. Additionally, due to mitotane-induced adrenal insufficiency, patients required a supraphysiological dose of hydrocortisone (HC), and in one patient, mineralocorticoid (MC) replacement with fludrocortisone was necessary. In 2 patients, hypothyroidism was diagnosed. All patients presented neurological symptoms of varying expression, which were more severe in younger children.

Conclusions
The side effects of using mitotane should be recognized quickly and adequately treated. In prepubertal children, PP could be a complication of therapy. The need to use supraphysiological doses of HC, sometimes with MC, should be highlighted. Some patients require levothyroxine replacement therapy. The neurotoxicity of mitotane is a significant clinical problem.

keywords:

puberty, adrenocortical carcinoma, mitotane, virilization

Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.